Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Hansoh Pharma
Biotech
Silence slows zerlasiran, as Hansoh leaves $1.3B biobucks collab
“We will only initiate the phase 3 cardiovascular outcomes study once a partner is secured,” Silence CEO Craig Tooman said.
James Waldron
Feb 27, 2025 8:51am
Merck pays $112M upfront for Hansoh's preclinical GLP-1
Dec 18, 2024 7:44am
Hansoh signs $690M ADC pact with fellow Chinese biotech Biotheus
Mar 15, 2024 8:35am
GSK heads back to Hansoh, paying $185M upfront for another ADC
Dec 20, 2023 9:01am
GSK pays $85M cash for China biotech's ADC
Oct 20, 2023 1:19pm
Chinese powerhouse continues charge into siRNA with Silence pact
Oct 15, 2021 7:15am